Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Arachidonoyl Ethanolamide-[1,2-14C] As A Substrate For Anandamide Amidase.

R. Omeir, S. Chin, Y. Hong, D. G. Ahern, D. Deutsch
Published 1995 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Arachidonoyl ethanolamide-[1,2-14C] was prepared and evaluated as a substrate for anandamide amidase in a radioenzymatic assay that does not require a thin layer chromatography separation step. Using this substrate the release of ethanolamine-[1,2-14C] is linear for approximately thirty minutes. Anandamide amidase exhibits maximal activity between pH 8 and pH 9 with a steep decline in activity at pH values below 6 and above 10. Arachidonoyl ethanolamide-[1,2-14C] was used for the assay of anandamide amidase from 10 micrograms to 100 micrograms protein, from cow brain homogenate, in a 0.2 ml incubation mixture. When plotted as a rectangular hyperbola of the steady-state Michaelis-Menten equation, an approximate Km of 30 +/- 7 microM and a Vmax of 198 +/- 13 nmoles ethanolamine formed per hour per mg protein homogenate was obtained.
This paper references
10.1126/SCIENCE.1470919
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
10.1016/0166-2236(90)90124-S
The cannabinoid receptor: biochemical, anatomical and behavioral characterization
A. Howlett (1990)
10.1016/0006-2952(94)90134-1
Effects of anandamide on cannabinoid receptors in rat brain membranes.
S. Childers (1994)
10.1021/JM00072A026
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor.
L. Hanuš (1993)
Inhibitors of arachidonoyl ethanolamide hydrolysis.
B. Koutek (1994)
10.1038/372686A0
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
V. Marzo (1994)
10.1016/0165-6147(94)90106-6
New dawn of cannabinoid pharmacology.
W. Devane (1994)
Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
K. Mackie (1993)
10.1016/0006-2952(93)90486-G
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.
D. Deutsch (1993)
10.1111/j.1471-4159.1984.tb12750.x
Catabolism of N‐Acylethanolamine Phospholipids by Dog Brain Preparations
V. Natarajan (1984)
10.1038/346561A0
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
L. Matsuda (1990)
10.1016/s0021-9258(17)38695-7
Properties of rat liver N-acylethanolamine amidohydrolase.
P. Schmid (1985)
10.1016/s0021-9258(18)96775-x
Microsomal synthesis of fatty acid amides.
N. Bachur (1966)
10.1021/JM00038A020
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
V. Abadji (1994)



This paper is referenced by
10.1016/J.EJPHAR.2006.11.025
Inhaled anandamide reduces leukotriene D4-induced airway obstruction in guinea pigs.
P. Stengel (2007)
10.1016/S0968-0896(02)00567-9
N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity.
S. Vandevoorde (2003)
10.14288/1.0066984
The endocannabinoid system as a novel target in the pathophysiology and treatment of depressive illness
M. Hill (2008)
10.1201/9781420023640.PT3
Occurrence, Biosynthesis, and Metabolism of Endocannabinoids
K. Waku (2005)
10.1038/sj.bjp.0706253
Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate
S. Vandevoorde (2005)
10.1038/npp.2009.114
Suppression of Amygdalar Endocannabinoid Signaling by Stress Contributes to Activation of the Hypothalamic-Pituitary-Adrenal Axis
M. Hill (2009)
10.1111/j.1471-4159.2007.04892.x
Changes in brain levels of N‐acylethanolamines and 2‐arachidonoylglycerol in focal cerebral ischemia in mice
M. Degn (2007)
10.1016/S0003-2697(03)00217-3
A high-throughput-compatible assay for determining the activity of fatty acid amide hydrolase.
S. Wilson (2003)
10.1037/e495572006-007
Inhibitors of anandamide breakdown.
D. Deutsch (1997)
Cannabinoid Properties of Methylfluorophosphonate Analogs 1
B. Martin (2000)
10.1038/sj.bjp.0704732
‘Entourage’ effects of N‐acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide‐induced vanilloid receptor activation and upon anandamide metabolism
D. Smart (2002)
10.1016/S0006-2952(01)00712-2
Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.
C. Fowler (2001)
10.1016/S0960-894X(98)00734-3
Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition.
D. Boger (1999)
[The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans].
J. Komorowski (2007)
10.1016/J.BMCL.2007.04.009
Novel inhibitors of fatty acid amide hydrolase.
S. Sit (2007)
10.1016/j.neuropharm.2007.05.015
Microglia produce and hydrolyze palmitoylethanolamide
G. Muccioli (2008)
10.1016/S0006-2952(99)00373-1
Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate.
G. Tiger (2000)
10.1021/JM050977K
Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates.
G. Muccioli (2006)
10.1177/1087057106288188
High-Throughput Screening for the Discovery of Inhibitors of Fatty Acid Amide Hydrolase Using a Microsome-Based Fluorescent Assay
Y. Wang (2006)
10.1159/000105671
A Bio-Psycho-Socio-Molecular Approach to Pain and Stress Management
T. Esch (2007)
10.1016/S0304-3940(97)00673-3
The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine
G. Arreaza (1997)
10.1016/S0014-5793(99)00774-7
Deletion of a proline‐rich region and a transmembrane domain in fatty acid amide hydrolase 1
G. Arreaza (1999)
10.1074/jbc.M003161200
The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase*
D. Deutsch (2001)
10.1080/1475636021000049726
Acidic Nonsteroidal Anti-inflammatory Drugs Inhibit Rat Brain Fatty Acid Amide Hydrolase in a pH-dependent Manner
C. Fowler (2003)
10.1016/j.neuroscience.2011.08.048
Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice
N. P. Bowles (2012)
10.1002/cmdc.201500395
A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation
R. Scarpelli (2016)
10.1006/BBRC.1999.1524
Identification of two serine residues involved in catalysis by fatty acid amide hydrolase.
R. Omeir (1999)
10.1054/PLEF.2001.0358
The fatty acid amide hydrolase (FAAH).
N. Ueda (2000)
10.1038/sj.bjp.0703569
Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase
C. Fowler (2000)
Endocannabinoids and N-acylethanolamines in translational pain research : from monoacylglycerol lipase to muscle pain
Nazdar Ghafouri (2013)
Cannabinoid properties of methylfluorophosphonate analogs.
B. Martin (2000)
10.1002/syn.21609
Temporal changes in N‐acylethanolamine content and metabolism throughout the peri‐adolescent period
T. T. Lee (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar